Status:

RECRUITING

Periodontal Microbiota in Systemic Sclerosis

Lead Sponsor:

University Hospital, Strasbourg, France

Conditions:

Scleroderma Systemic

Eligibility:

All Genders

18+ years

Phase:

NA

Brief Summary

Systemic sclerosis (SSc) is a rare and complex autoimmune disease. Although its etiology remains unknown, various environmental factors, including certain microorganisms, can represent potential trigg...

Eligibility Criteria

Inclusion

  • Common inclusion criteria
  • Men or women over 18 (adults)
  • Affiliation to a social health insurance plan
  • Subject able to understand the aims and risks of the research and to give signed informed consent form prior to the inclusion in the study
  • More than 12 teeth suitable for evaluation
  • Inclusion criteria for systemic sclerosis patients
  • Systemic sclerosis patient with a diagnosis based on the American College of Rheumatology/European League Against Rheumatism criteria (LeRoy et al., 1988 ; van den Hoogen et al., 2013)
  • Diagnosis made during the 2 years preceding study inclusion (early form of the disease)
  • Inclusion criteria for controls
  • \- Patient attending the Oral Medicine and Surgery Department from the University Hospital of Strasbourg for a routine dental consultation

Exclusion

  • \- Subject under court protection
  • Subject under guardianship or curatorship
  • Pregnancy or breastfeeding
  • Impossibility to provide accurate information (emergency situation, comprehension difficulties…)
  • Subject currently involved in another clinical trial or in an exclusion period following participation in another clinical trial
  • Smoking (≥ 10 cigarettes per day)
  • Other associated systemic auto-immune disease (Sjögren syndrome with positive serum anti-SSA and/or anti-SSB auto-antibodies, systemic lupus erythematosus…)
  • Progressive chronic illness other than systemic sclerosis
  • Acute infection at inclusion
  • Progressive cancer or cancer diagnosed within 2 years prior to the study
  • Ongoing antibiotic and/or antifungal treatment or within 3 months prior to inclusion
  • Probiotics and/or prebiotics intake within 3 months prior to inclusion
  • Oral antiseptics within the week before inclusion (chlorhexidin mouthwashes…)
  • Risk of infective endocarditis
  • Corticosteroids ≥10 mg/day and/or proton pump inhibitors within 3 months prior to inclusion
  • Previous hematopoietic stem cell transplantation
  • Another cause of skin sclerosis (radiotherapy of the orofacial area…)
  • Periodontal specialized treatments, root and/or periodontal surgical treatment and/or subgingival instrumentation within the year before inclusion

Key Trial Info

Start Date :

October 24 2024

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

October 24 2025

Estimated Enrollment :

30 Patients enrolled

Trial Details

Trial ID

NCT06182293

Start Date

October 24 2024

End Date

October 24 2025

Last Update

August 6 2025

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Clinique Dentaire

Strasbourg, France, 67000